antihypertensive + statin + antiplatelet

This refers to a combination therapy or fixed-dose combination (FDC) that includes three pharmacological classes commonly used in cardiovascular disease prevention and management: - **Antihypertensive** drugs lower blood pressure through various mechanisms, such as vasodilation, diuresis, or inhibition of the renin-angiotensin system. - **Statins** are lipid-lowering agents that inhibit HMG-CoA reductase, reducing cholesterol synthesis and increasing LDL receptor availability to lower LDL cholesterol. - **Antiplatelet** agents (such as low-dose acetylsalicylic acid/aspirin) inhibit platelet aggregation to reduce thrombotic risk. Such combinations target multiple cardiovascular risk factors simultaneously—hypertension, hyperlipidemia, and thrombosis—to provide additive or synergistic protection against major adverse cardiovascular events like myocardial infarction and stroke. While fixed-dose combinations of antihypertensives with statins are available (e.g., amlodipine/atorvastatin), the addition of an antiplatelet agent is typically prescribed separately but may be considered for high-risk patients[1][3][4]. The rationale for this triple therapy is supported by clinical trials showing improved outcomes when all three risk factors are managed together[2][3][6].